63 patents
Utility
Transient Protection of Normal Cells During Chemotherapy
30 Nov 23
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 7 Aug 23
Utility
Hspc-sparing Treatments for Rb-positive Abnormal Cellular Proliferation
16 Nov 23
This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
Filed: 6 Mar 23
Utility
Preservation of Immune Response During Chemotherapy Regimens
28 Sep 23
The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer.
Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick Joseph Roberts
Filed: 1 Dec 22
Utility
Highly Active Anti-neoplastic and Anti-proliferative Agents
10 Aug 23
This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 17 Aug 22
Utility
Transient protection of normal cells during chemotherapy
8 Aug 23
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 5 Apr 21
Utility
Anti-neoplastic Combinations and Dosing Regimens Using CDK4/6 Inhibitor Compounds to Treat Rb-positive Tumors
3 Aug 23
This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes.
Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
Filed: 29 Aug 22
Utility
Synthesis of 1,4-diazaspiro[5.5]undecan-3-one
25 Jul 23
This invention provides a process for preparing 1,4-diazaspiro[5.5]undecan-3-one and analogues thereof that are useful in the preparation of pharmaceutical compound, including for the treatment of disorders involving abnormal cellular proliferation.
Stephen E. Schneider, Hannah White, Thomas Fessard, Sagar Beldar
Filed: 24 Feb 21
Utility
HSPC-sparing treatments for RB-positive abnormal cellular proliferation
23 May 23
This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
Filed: 22 Feb 21
Utility
G1T38 Superior Dosage Regimes
18 May 23
A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
Andrew Beelen, Jay Copeland Strum
Filed: 13 Jun 22
Utility
Treatment of EGFR-Driven Cancer with Fewer Side Effects
11 May 23
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs.
Jessica A. Sorrentino, Jay Copeland Strum, John E. Bisi, Andrew Beelen
Filed: 30 Jun 22
Utility
Substituted 1′,2′-dihydro-3′H-spiro[cyclohexane-1,4′-pyrimido[5′,4′:4,5]pyrrolo[2,1-c][1,2,4]triazin]-3′-ones as cyclin-dependent kinase inhibitors
9 May 23
Jay Copeland Strum
Filed: 11 May 22
Utility
Synthesis of N-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
18 Apr 23
This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
Filed: 14 Dec 20
Utility
Morphic Forms of G1T38 and Methods of Manufacture Thereof
9 Feb 23
Alexander Smith, Hannah S. White, Patricia Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
Filed: 28 Feb 22
Utility
Preservation of immune response during chemotherapy regimens
20 Dec 22
The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer.
Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick Joseph Roberts
Filed: 5 Jun 19
Utility
Cyclin-dependent Kinase Inhibiting Compounds for the Treatment of Medical Disorders
29 Sep 22
This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.
Jay Copeland Strum
Filed: 11 May 22
Utility
Anti-neoplastic combinations and dosing regimens using CDK4/6 inhibitor compounds to treat Rb-positive tumors
20 Sep 22
This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes.
Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
Filed: 22 Jan 19
Utility
Targeted Treatment of Cancers with Dysregulated Fibroblast Growth Factor Receptor Signaling
4 Aug 22
The present invention provides advantageous methods and compositions for treating a host having a cancer with dysregulation of the FGFR signaling pathway, which includes administering an effective amount of a selective CDK4/6 inhibitor described herein in combination or alternation with a fibroblast growth factor receptor inhibitor.
Jay Copeland Strum, Chloe Whitworth, Daniel M. Freed
Filed: 11 Apr 22
Utility
Treatment of EGFR-driven cancer with fewer side effects
26 Jul 22
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs.
Jessica A. Sorrentino, Jay Copeland Strum, John E. Bisi, Andrew Beelen
Filed: 21 Aug 19
Utility
Combination therapy for treatment of cancer
21 Jun 22
Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.
Jay C. Strum, Gregory R. Thatcher, Rui Xiong, Jiong Zhao, Debra A. Tonetti
Filed: 2 Jul 19
Utility
G1T38 superior dosage regimes
14 Jun 22
A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
Andrew Beelen, Jay Copeland Strum
Filed: 8 Jul 20